Association of Genetic Variation in the MET Proto-Oncogene With Schizophrenia and General Cognitive Ability

被引:31
|
作者
Burdick, Katherine E. [1 ]
DeRosse, Pamela
Kane, John M.
Lencz, Todd
Malhotra, Anil K.
机构
[1] Zucker Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Dept Psychiat Res, Glen Oaks, NY 11004 USA
来源
AMERICAN JOURNAL OF PSYCHIATRY | 2010年 / 167卷 / 04期
关键词
HEPATOCYTE GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; INTERNEURON DEVELOPMENT; CANCER-RISK; AUTISM; SUSCEPTIBILITY; DISRUPTION; MEDICATION; PARENTS; PATHWAY;
D O I
10.1176/appi.ajp.2009.09050615
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: Despite increased exposure to cancer risk factors, several studies have demonstrated a lower incidence of cancer in schizophrenia patients than in the general population. Lower cancer rates in first-degree relatives of schizophrenia patients suggest that the inverse relationship between cancer and schizophrenia may be related to genetic factors. Few studies of schizophrenia have focused on cancer-related genes. The MET proto-oncogene is primarily linked to tumor metastasis, but MET is also involved in neurodevelopment and influences risk for autism. Thus, MET may be of particular interest as a candidate gene for neuropsychiatric diseases with a developmental etiology, including schizophrenia. Method: The authors examined the relationship between 21 single-nucleotide polymorphisms in MET and schizophrenia in 173 Caucasian patients and 137 comparison subjects. They then genotyped a second independent sample (107 patients and 112 comparison subjects) for replication. Finally, they tested for MET's effects on general cognitive ability (g). Results: In the initial cohort, the authors identified four haplotype blocks and found one block to be globally associated with schizophrenia. In block 3, the most common haplotype was over-represented in comparison subjects (frequency, 47%) relative to schizophrenia patients (frequency, 33%) (p=4.0x10(-4); odds ratio=0.56). The authors replicated the block 3 finding in the second sample with similar frequencies: 46% in comparison subjects and 36% in schizophrenia patients (p=0.03; odds ratio=0.66). Moreover, the protective haplotype was associated with a higher g in the combined comparison sample. Conclusions: These data suggest that MET variation influences schizophrenia risk and neurocognition, supporting a neurodevelopmental role across CNS-relevant phenotypes. These results add to the growing evidence suggesting an intriguing relationship between cancer-related genes and schizophrenia susceptibility.
引用
收藏
页码:436 / 443
页数:8
相关论文
共 50 条
  • [41] Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth
    Keiji Inoue
    Takashi Karashima
    Masakazu Chikazawa
    Tatsuo Iiyama
    Chiaki Yoshikawa
    M. Furihata
    Yuji Ohtsuki
    Taro Shuin
    Virchows Archiv, 1998, 433 : 511 - 515
  • [42] Overexpression of c-MET proto-oncogene in chromophilic renal cell carcinoma with papillary growth.
    Inoue, K
    Chikazawa, M
    Furihata, M
    Ohtsuki, Y
    Kataoka, S
    Komatsu, F
    Karashima, T
    Shuin, T
    JOURNAL OF UROLOGY, 1998, 159 (05): : 188 - 188
  • [43] Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours
    Joachim Fischer
    Gabriele Palmedo
    Rolf von Knobloch
    Peter Bugert
    Thomas Prayer-Galetti
    Francesco Pagano
    Gyula Kovacs
    Oncogene, 1998, 17 : 733 - 739
  • [44] Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma
    Ueki, T
    Fujimoto, J
    Suzuki, T
    Yamamoto, H
    Okamoto, E
    HEPATOLOGY, 1997, 25 (03) : 619 - 623
  • [45] Expression of the c-Met Proto-Oncogene and Integrin α5β1 in Human Gastric Cardia Adenocarcinoma
    Chi, Fusheng
    Fu, Da
    Zhang, Xiaoping
    Lv, Zhongwei
    Wang, Zhesheng
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2012, 76 (08) : 1471 - 1476
  • [46] Uncommon association of germline mutations of RET proto-oncogene and CDKN2A gene
    Foppiani, L.
    Forzano, F.
    Cecchcrini, I.
    Bruno, W.
    Ghiorzo, P.
    Caroli, F.
    Quilici, P.
    Bandelloni, R.
    Arlandini, A.
    Sartini, G.
    Cabria, M.
    Del Monte, P.
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) : 417 - 422
  • [48] Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease
    Teofili, L
    Di Febo, AL
    Pierconti, F
    Maggiano, N
    Bendandi, M
    Rutella, S
    Cingolani, A
    Di Renzo, N
    Musto, P
    Pileri, S
    Leone, G
    Larocca, LM
    BLOOD, 2001, 97 (04) : 1063 - 1069
  • [49] Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth
    Inoue, K
    Karashima, T
    Chikazawa, M
    Iiyama, T
    Yoshikawa, C
    Furihata, M
    Ohtsuki, Y
    Shuin, T
    VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY, 1998, 433 (06): : 511 - 515
  • [50] Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours
    Fischer, J
    Palmedo, G
    von Knobloch, R
    Bugert, P
    Prayer-Galetti, T
    Pagano, F
    Kovacs, G
    ONCOGENE, 1998, 17 (06) : 733 - 739